Literature DB >> 10448007

CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.

Q Sun1, R L Burton, K E Pollok, D J Emanuel, K G Lucas.   

Abstract

Umbilical cord blood (CB) is increasingly used for allogeneic hematopoietic stem cell transplantation. To determine whether viral antigen-specific cytotoxic T-lymphocytes (CTL) could be generated from the predominantly naive T-cell populations in CB, CB-derived mononuclear cells were stimulated with autologous Epstein-Barr virus (EBV) transformed B-lymphoblastoid cell lines over several weeks in the presence of recombinant human interleukin-2 (IL-2). By 28 days of culture, T-lymphocytes from all six CB that had been treated with IL-2 displayed EBV-specific cytotoxicity. These cells were largely CD4(+), with complete inhibition of cytotoxicity by anti-CD3 and variable inhibition by anti-HLA DR monoclonal antibodies. The EBV-specific effectors were cloned by limiting dilution, and most of the CTL clones were CD4(+). The cytotoxicity of the CB-derived CD4(+) CTL clones was inhibited by EGTA but not by anti-Fas ligand mAb, suggesting that this cytotoxicity was mediated by perforin/granzyme B. These data indicate that virus-specific CTL can be cultivated and cloned from CB, a human T-cell source that may not have prior in vivo antigenic exposure or reactivity. This finding may have applications in adoptive immunotherapy to recipients of CB transplants. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448007     DOI: 10.1006/cimm.1999.1514

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  20 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Authors:  Noémi Nagy; Mónika Adori; Abu Rasul; Frank Heuts; Daniel Salamon; Dorina Ujvári; Harsha S Madapura; Benjamin Leveau; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 4.  Neonatal innate immunity to infectious agents.

Authors:  László Maródi
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

5.  The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.

Authors:  Austin John Barrett; Catherine M Bollard
Journal:  Ann Transl Med       Date:  2015-04

Review 6.  Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.

Authors:  Patrick J Hanley; Catherine M Bollard; Claudio G Brunstein
Journal:  Cytotherapy       Date:  2015-01-24       Impact factor: 5.414

7.  Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.

Authors:  Allistair A Abraham; Tami D John; Michael D Keller; C Russell N Cruz; Baheyeldin Salem; Lauren Roesch; Hao Liu; Fahmida Hoq; Bambi J Grilley; Adrian P Gee; Hema Dave; David A Jacobsohn; Robert A Krance; Elizabeth J Shpall; Caridad A Martinez; Patrick J Hanley; Catherine M Bollard
Journal:  Blood Adv       Date:  2019-07-23

Review 8.  Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Authors:  Patrick J Hanley; Conrad Russell Cruz; Elizabeth J Shpall; Catherine M Bollard
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

9.  Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus.

Authors:  Matthieu Perreau; Eric J Kremer
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

10.  Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.

Authors:  Yoshinari Kawabata; Makoto Hirokawa; Yoshinobu Saitoh; Shigeki Kosugi; Tomoko Yoshioka; Masumi Fujishima; Naohito Fujishima; Yoshihiro Kameoka; Hirobumi Saitoh; Masaaki Kume; Naoto Takahashi; Ken-ichi Sawada
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.